معرفی
Yuhong Lu is an Associate Research Scientist in the Department of Therapeutic Radiology at Yale School of Medicine. She holds a PhD from McGill University (2004) and an MD from West China University of Medical Sciences (1993). Her research focuses on tumor hypoxia, DNA repair mechanisms, and drug resistance in cancer. Key areas include hypoxia-induced epigenetic silencing of tumor suppressor genes (e.g., BRCA1 and MLH1) and mechanisms of resistance to targeted therapies like EGFR inhibitors. Collaborations with prominent researchers like Peter M. Glazer and Ranjit S. Bindra underscore her contributions to understanding cancer biology. Recent work highlights roles of histone demethylases (e.g., LSD1) and oncometabolites in hypoxia-driven resistance. Lu’s studies have been published in high-impact journals such as Molecular and Cellular Biology and PNAS.
Her research spans translational studies on hypoxia’s impact on DNA repair pathways and tumor progression. Notable findings include hypoxia-induced BRCA1 promoter silencing via epigenetic modifications and the synergy between hypoxia and oncometabolites in suppressing STING signaling. Lu’s work also explores combinatorial therapies targeting IGF-1R and HER2 receptors in breast cancer, emphasizing molecular mechanisms of drug resistance.
- Education: PhD, McGill University (2004); MD, West China University of Medical Sciences (1993)
- Key Collaborators: Peter Glazer, Ranjit Bindra
- Research Themes: Tumor hypoxia, DNA repair, epigenetic regulation, drug resistance in cancer
Recent publications (2016–2023) emphasize hypoxia’s role in modulating EGFR inhibitor resistance via FGFR1 and EMT pathways, as well as histone demethylase-driven silencing of DNA repair genes. This work bridges basic science and clinical applications in radiation oncology and targeted therapy.
